Cargando…

Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS

OBJECTIVE: To evaluate (1) the frequency of aquaporin-4 antibody (AQP4-ab)-seropositive cases among patients treated with natalizumab (NAT) and previously diagnosed with MS (MS(NAT)) in a nationwide cohort, (2) the clinical course of NAT-treated AQP4-ab–seropositive neuromyelitis optica spectrum dis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gahlen, Anna, Trampe, Anne-Kathrin, Haupeltshofer, Steffen, Ringelstein, Marius, Aktas, Orhan, Berthele, Achim, Wildemann, Brigitte, Gold, Ralf, Jarius, Sven, Kleiter, Ingo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473957/ https://www.ncbi.nlm.nih.gov/pubmed/28642888 http://dx.doi.org/10.1212/NXI.0000000000000363

Ejemplares similares

Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate
por: Jarius, Sven, et al.
Publicado: (2014)

Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)
por: Trebst, Corinna, et al.
Publicado: (2013)

Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis
por: Jarius, Sven, et al.
Publicado: (2023)

Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder: A Cross-Sectional Study of 166 AQP4 Antibody–Seropositive Patients
por: Ayzenberg, Ilya, et al.
Publicado: (2021)

Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study
por: Jarius, Sven, et al.
Publicado: (2014)

Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis
por: Metz, Imke, et al.
Publicado: (2016)

Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients
por: Dahlhaus, Stefanie, et al.
Publicado: (2013)

Bridging, switching or drug holidays – how to treat a patient who stops natalizumab?
por: Havla, Joachim, et al.
Publicado: (2013)

Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy
por: Jarius, Sven, et al.
Publicado: (2016)

Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions
por: Kleiter, Ingo, et al.
Publicado: (2018)

Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response
por: Stellmann, Jan-Patrick, et al.
Publicado: (2017)

Interferon-β-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab
por: Harmel, Jens, et al.
Publicado: (2014)

Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody–Associated Disease: CHANCE(NMO) Study
por: Hümmert, Martin W., et al.
Publicado: (2022)

Cognition in patients with neuromyelitis optica spectrum disorders: A prospective multicentre study of 217 patients (CogniNMO-Study)
por: Hümmert, Martin W, et al.
Publicado: (2023)

Fingolimod for Irradiation-Induced Neurodegeneration
por: Metzdorf, Judith, et al.
Publicado: (2019)

Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica
por: Waters, Patrick, et al.
Publicado: (2016)

Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG–Associated Disease and Neuromyelitis Optica Spectrum Disorders
por: Ringelstein, Marius, et al.
Publicado: (2021)

Antibody to Aquaporin 4 in the Diagnosis of Neuromyelitis Optica
por: Paul, Friedemann, et al.
Publicado: (2007)

The history of neuromyelitis optica
por: Jarius, Sven, et al.
Publicado: (2013)

Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance
por: Jarius, Sven, et al.
Publicado: (2010)

Progressive Retinal and Optic Nerve Damage in a Mouse Model of Spontaneous Opticospinal Encephalomyelitis
por: Petrikowski, Laura, et al.
Publicado: (2022)

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin
por: Jarius, Sven, et al.
Publicado: (2016)

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome
por: Jarius, Sven, et al.
Publicado: (2016)

Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients
por: Jarius, Sven, et al.
Publicado: (2020)

Pharmacodynamics of natalizumab extended interval dosing in MS
por: Zhovtis Ryerson, Lana, et al.
Publicado: (2020)

Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS
por: Hodecker, Sibylle C., et al.
Publicado: (2017)

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients
por: Jarius, Sven, et al.
Publicado: (2022)

Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody–Associated Diseases: COPANMO(G)-Study
por: Hümmert, Martin W., et al.
Publicado: (2023)

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients
por: Plavina, Tatiana, et al.
Publicado: (2017)

Patterns of Retinal Damage Facilitate Differential Diagnosis between Susac Syndrome and MS
por: Brandt, Alexander U., et al.
Publicado: (2012)

Rho GTPase-activating protein 17 (ARHGAP17) as additional autoimmune target in ARHGAP26-IgG/anti-Ca autoantibody-associated autoimmune encephalitis
por: Jarius, Sven, et al.
Publicado: (2022)

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome
por: Jarius, Sven, et al.
Publicado: (2016)

Natalizumab in the pediatric MS population: results of the Italian registry
por: Ghezzi, Angelo, et al.
Publicado: (2015)

Improvement of Comorbid Psoriasis in Patients With MS Treated With Natalizumab
por: Berkovich, Regina, et al.
Publicado: (2021)

Pattern II and pattern III MS are entities distinct from pattern I MS: evidence from cerebrospinal fluid analysis
por: Jarius, S., et al.
Publicado: (2017)

Aquaporin-4 Antibodies Are Not Related to HTLV-1 Associated Myelopathy
por: von Glehn, Felipe, et al.
Publicado: (2012)

Relapse-independent multiple sclerosis progression under natalizumab
por: Graf, Jonas, et al.
Publicado: (2021)

COVID-19-related severe MS exacerbation with life-threatening Takotsubo cardiomyopathy in a previously stable patient and interference of MS therapy with long-term immunity against SARS-CoV-2
por: Wildemann, Brigitte, et al.
Publicado: (2021)

Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75
por: Krumbholz, Markus, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_332q9il0hjb12l51i5deku1tnk